Lilly’s Tirzepatide Shows Benefit In Heart Failure, Including Outcomes

 
• By Jessica Merrill

Lilly is the first to demonstrate a benefit on heart failure outcomes with an incretin, even though rival Novo Nordisk already filed heart failure data for Wegovy with the US FDA. 

Lilly's tirzepatide showed a benefit in heart failure • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas